Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-18 23:50 | 2025-06-16 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | Officer | OPT+S | $19.29 | 100,000 | $1,929,140 | 44,000 |
| 2025-06-19 01:22 | 2025-06-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $22.18 | 12,500 | $277,293 | 952,892 |
| 2025-06-19 01:04 | 2025-06-17 | ARVN | Arvinas Inc. | Cacace Angela M | Officer | SELL | $7.49 | 2,583 | $19,347 | 154,248 |
| 2025-06-19 00:18 | 2025-06-16 | IRON | Disc Medicine, Inc. | Franchi Jean M. | Officer | SELL | $52.26 | 2,000 | $104,519 | 67,530 |
| 2025-06-19 00:12 | 2025-06-16 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | SELL | $266.50 | 422 | $112,463 | 0 |
| 2025-06-19 00:10 | 2025-06-16 | ONC | BeOne Medicines Ltd. | Wang Lai | Officer | SELL | $262.11 | 1,647 | $431,699 | 0 |
| 2025-06-19 00:08 | 2025-06-16 | ONC | BeOne Medicines Ltd. | Wu Xiaobin | Officer | SELL | $261.27 | 2,173 | $567,742 | 0 |
| 2025-06-19 01:02 | 2025-06-17 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Officer | SELL | $30.24 | 911 | $27,549 | 50,392 |
| 2025-06-19 04:16 | 2025-06-16 | AXSM | Axsome Therapeutics, Inc. | Murdock Hunter R. | Officer | OPT+S | $101.19 | 22,500 | $2,276,849 | 0 |
| 2025-06-18 15:49 | 2025-06-16 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $18.77 | 5,000 | $93,850 | 133,730 |
| 2025-06-18 23:57 | 2025-06-16 | XLO | Xilio Therapeutics, Inc. | Shannon James Samuel | Director | BUY | $0.69 | 70,000 | $48,083 | 70,000 |
| 2025-06-19 01:45 | 2025-06-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | Officer | SELL | $1.15 | 6,422 | $7,398 | 401,241 |
| 2025-06-19 01:44 | 2025-06-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Director, Officer | SELL | $1.11 | 30,474 | $33,796 | 1,541,488 |
| 2025-06-19 01:44 | 2025-06-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | Officer | SELL | $1.15 | 7,229 | $8,328 | 474,473 |
| 2025-06-18 16:11 | 2025-06-17 | IMRX | Immuneering Corp | Schall Thomas J. | Director | BUY | $2.21 | 40,485 | $89,278 | 43,385 |
| 2025-06-18 23:05 | 2025-06-16 | NUVB | Nuvation Bio Inc. | Wentworth Kerry | Officer | BUY | $1.79 | 50,000 | $89,740 | 50,000 |
| 2025-06-18 23:42 | 2025-06-16 | NAMS | NewAmsterdam Pharma Co N.V. | Topper James N | Director | BUY | $19.50 | 8,584 | $167,381 | 3,022,153 |
| 2025-06-18 23:05 | 2025-06-16 | NUVB | Nuvation Bio Inc. | Hung David | Director, Officer, 10% owner | BUY | $1.79 | 500,000 | $893,500 | 59,281,054 |
| 2025-06-19 04:28 | 2025-06-16 | ARDX | Ardelyx Inc. | MOTT DAVID M | Director | BUY | $3.63 | 200,000 | $725,880 | 2,896,871 |
| 2025-06-18 23:32 | 2024-05-13 | TRDA | Entrada Therapeutics, Inc. | KIM PETER S | Director | BUY | $14.63 | 50,000 | $731,680 | 117,412 |
| 2025-06-19 00:10 | 2025-06-17 | OGEN | ORAGENICS INC | Odyssey Health, Inc. | 10% owner | SELL | $4.32 | 7,044 | $30,408 | 0 |
| 2025-06-18 23:16 | 2025-06-16 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $100.39 | 135,009 | $13,553,743 | 233,924 |
| 2025-06-18 23:15 | 2025-06-16 | INSM | INSMED Inc | Adsett Roger | Officer | SELL | $98.82 | 10,686 | $1,056,003 | 130,637 |
| 2025-06-19 01:26 | 2025-06-16 | CORT | CORCEPT THERAPEUTICS INC | Robb Gary Charles | Officer | SELL | $70.77 | 3,185 | $225,402 | 13,364 |
| 2025-06-19 00:06 | 2025-06-16 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer | SELL | $263.33 | 5,140 | $1,353,520 | 0 |
| 2025-06-17 23:31 | 2025-06-16 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $76.93 | 27,000 | $2,077,094 | 249,062 |
| 2025-06-18 04:30 | 2025-06-13 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% owner | BUY | $0.41 | 5,000 | $2,068 | 33,237,968 |
| 2025-06-17 23:11 | 2025-06-13 | LFVN | Lifevantage Corp | Lewis Darwin | Director | BUY | $12.86 | 379 | $4,873 | 116,767 |
| 2025-06-17 23:24 | 2025-06-13 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $22.55 | 3,000 | $67,655 | 23,000 |
| 2025-06-17 23:11 | 2025-06-13 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | Officer | OPT+S | $2.72 | 12,255 | $33,381 | 226,271 |
| 2025-06-17 23:10 | 2025-06-16 | CTMX | CytomX Therapeutics, Inc. | BELVIN MARCIA | Officer | OPT+S | $2.69 | 13,884 | $37,334 | 272,252 |
| 2025-06-17 23:09 | 2025-06-16 | CTMX | CytomX Therapeutics, Inc. | McCarthy Sean A. | Director, Officer | OPT+S | $2.69 | 55,511 | $149,264 | 1,089,684 |
| 2025-06-18 02:55 | 2025-06-13 | PBYI | PUMA BIOTECHNOLOGY, INC. | WILSON TROY EDWARD | Director | SELL | $3.40 | 10,800 | $36,720 | 43,550 |
| 2025-06-18 02:52 | 2025-06-13 | PBYI | PUMA BIOTECHNOLOGY, INC. | Stuglik Brian M | Director | SELL | $3.39 | 8,100 | $27,459 | 94,958 |
| 2025-06-18 02:49 | 2025-06-13 | PBYI | PUMA BIOTECHNOLOGY, INC. | Senderowicz Adrian | Director | SELL | $3.40 | 27,000 | $91,800 | 27,000 |
| 2025-06-18 02:43 | 2025-06-13 | PBYI | PUMA BIOTECHNOLOGY, INC. | Dorval Allison | Director | SELL | $3.40 | 11,610 | $39,474 | 75,390 |
| 2025-06-18 02:41 | 2025-06-13 | PBYI | PUMA BIOTECHNOLOGY, INC. | Cesano Alessandra | Director | SELL | $3.40 | 12,150 | $41,310 | 68,850 |
| 2025-06-17 23:44 | 2025-06-13 | BHC | Bausch Health Companies Inc. | Paulson John | Director | BUY | $5.94 | 3,564,059 | $21,170,510 | 32,791,702 |
| 2025-06-18 00:45 | 2025-06-13 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | BUY | $13.08 | 2,646 | $34,610 | 27,448 |
| 2025-06-17 23:35 | 2025-06-13 | PTN | PALATIN TECHNOLOGIES INC | DUNTON ALAN W | Director | BUY | $20,000.00 | 200 | $4,000,000 | 224,112 |
| 2025-06-18 02:46 | 2025-06-13 | PBYI | PUMA BIOTECHNOLOGY, INC. | MOYES JAY M | Director | SELL | $3.40 | 22,000 | $74,800 | 53,322 |
| 2025-06-17 23:35 | 2025-06-13 | PTN | PALATIN TECHNOLOGIES INC | WILLS STEPHEN T | Officer | BUY | $150,000.00 | 1,500 | $225,000,000 | 1,640,756 |
| 2025-06-17 23:27 | 2025-06-17 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $32.91 | 2,000 | $65,820 | 140,610 |
| 2025-06-17 23:35 | 2025-06-13 | PTN | PALATIN TECHNOLOGIES INC | SPANA CARL | Director, Officer | BUY | $150,000.00 | 1,500 | $225,000,000 | 1,672,940 |
| 2025-06-16 23:26 | 2025-06-13 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | Officer | BUY | $4.38 | 25,000 | $109,475 | 1,708,585 |
| 2025-06-16 23:03 | 2025-06-12 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Kalif Eliyahu Sharon | Officer | SELL | $17.08 | 55,775 | $952,464 | 403,288 |
| 2025-06-17 00:00 | 2025-06-12 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% owner | BUY | $0.42 | 70,000 | $29,099 | 33,232,968 |
| 2025-06-16 23:56 | 2025-06-12 | ETON | Eton Pharmaceuticals, Inc. | Krempa David | Officer | SELL | $14.83 | 34,000 | $504,319 | 612,646 |
| 2025-06-16 23:03 | 2025-06-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $14.60 | 11,366 | $165,931 | 101,651 |
| 2025-06-16 23:48 | 2025-06-12 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Officer | OPT+S | $32.23 | 97,483 | $3,141,877 | 99,713 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.